Pathogenic Variants in <i>A</i> <i>TP1A3</i>
Dominant pathogenic variants in ATP1A3 can occur anywhere in the coding sequence and can cause a wide range of clinical presentations. A practical problem is that sequencing services use one of 3 different mRNA transcripts with different lengths to number the candidate variants. Genetic reports often identify an ATP1A3 variant as a VUS when it is actually well validated. Only 1 transcript, the MANE Select transcript that encodes a protein of 1,013 amino acids, is well supported by evidence. Misidentification of variants in ATP1A3 is disadvantageous when it prevents a confident diagnosis. We illustrate the differences among the 3 transcripts and their merits. Sequencing services should use the MANE Select transcript.
Authors
- Laurie J. Ozelius (ORCID: https://orcid.org/0000-0002-7820-1684)
- Ihtsham Haq (ORCID: https://orcid.org/0000-0002-8001-8440)
- Kathleen J. Sweadner (ORCID: https://orcid.org/0000-0002-2817-5262)
- Allison Brashear (ORCID: https://orcid.org/0000-0002-8812-7545)
- Elena Arystarkhova (ORCID: https://orcid.org/0009-0000-5334-6038)
Institutions
- Harvard University (US)
- University of Miami (US)
- Massachusetts General Hospital (US)
- Jacobs Institute (US)
- University at Buffalo, State University of New York (US)
Publication Details
- Journal
- Neurology Genetics
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1212/nxg.0000000000200320
- Primary Topic
- Genomics and Rare Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00